12 Most Undervalued Stocks to Invest In
Undervalued stocks are getting more attention as investors look for opportunities outside the crowded growth trade.
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 29,631,105 | $1,797,126,523 | +15% | 0.82% |
| 2. | Pzena Investment Management Richard S. Pzena | 17,095,731 | $1,036,856,085 | -5% | 3.37% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 11,535,106 | $699,604,179 | +40% | 0.56% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 8,872,779 | $538,134,046 | -49% | 0.29% |
| 5. | Millennium Management Israel Englander | 6,545,442 | $396,981,057 | +781% | 0.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.05 | 4,481 | $278,046.05 | 159,248 | 2026-04-01 | Filing | |
| $61.60 | 25,519 | $1,571,970.40 | 163,729 | 2026-04-01 | Filing | |
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 171,682,888 | $10,412,567,160 | 0.18% | |
| 2. | 132,320,240 | $8,025,222,556 | 0.19% | |
| 3. | 98,564,914 | $5,977,962,034 | 0.21% | |
| 4. | 92,475,194 | $5,523,543,465 | 0.35% | |
| 5. | 61,115,373 | $3,706,647,372 | 0.57% |
News See All
BMO Capital Maintains Market Perform Rating on Bristol-Myers (BMY) After Earnings Beat
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best retirement stocks to buy now.
8 Best Retirement Stocks to Buy Now
A great many people struggle to determine how much money they will need to live comfortably in retirement, especially as retirement expenses rise annually.
12 Best Dividend Stocks to Invest In According to Hedge Funds
Investors tend to favor dividend stocks in times of market volatility and economic uncertainty, as we have seen in recent months.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript
Operator: Welcome to the Bristol-Myers Squibb First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
14 Best Defensive Stocks to Invest In Now
The US economy has entered the final week of April navigating a precarious war-driven landscape that has fundamentally altered the outlook for both growth and monetary policy.
15 Cash-Rich Dividend Stocks to Invest In Right Now
On March 24, Reuters reported that Barclays raised its 2026 year-end S&P 500 target.
15 Blue Chip Stocks with Highest Dividends
Blue-chip stocks refer to shares of large, well-established companies that lead their industries. These businesses are typically financially strong, which makes them less risky compared to others.
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in now. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 29 positive data from the Phase 3 SCOUT-HCM trial...
Hedge Fund Resource Center